References
- Wong TY, Chakravarthy U, Klein R, et al. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology 2008;115:116-26. https://doi.org/10.1016/j.ophtha.2007.03.008
- Park SJ, Kwon KE, Choi NK, et al. Prevalence and incidence of exudative age-related macular degeneration in South Korea: a nationwide population-based study. Ophthalmology 2015;122: 2063-70.e1. https://doi.org/10.1016/j.ophtha.2015.06.018
- Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355:1419-31. https://doi.org/10.1056/NEJMoa054481
- Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012;119:2537-48. https://doi.org/10.1016/j.ophtha.2012.09.006
- Grunwald JE, Daniel E, Huang J, et al. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology 2014;121:150-61. https://doi.org/10.1016/j.ophtha.2013.08.015
- Kruger Falk M, Kemp H, Sorensen TL. Four-year treatment results of neovascular age-related macular degeneration with ranibizumab and causes for discontinuation of treatment. Am J Ophthalmol 2013;155:89-95.e3. https://doi.org/10.1016/j.ajo.2012.06.031
- Zhu M, Chew JK, Broadhead GK, et al. Intravitreal ranibizumab for neovascular age-related macular degeneration in clinical practice: five-year treatment outcomes. Graefes Arch Clin Exp Ophthalmol 2015;253:1217-25. https://doi.org/10.1007/s00417-014-2799-8
- Berg K, Roald AB, Navaratnam J, Bragadottir R. An 8-year follow-up of anti-vascular endothelial growth factor treatment with a treat-and-extend modality for neovascular age-related macular degeneration. Acta Ophthalmol 2017;95:796-802. https://doi.org/10.1111/aos.13522
- Garweg JG, Zirpel JJ, Gerhardt C, Pfister IB. The fate of eyes with wet AMD beyond four years of anti-VEGF therapy. Graefes Arch Clin Exp Ophthalmol 2018;256:823-31. https://doi.org/10.1007/s00417-018-3907-y
- Jang HJ, Song SJ, Bae JH. Long-term effect of intravitreal ranibizumab injection on choroidal neovascularization in age-related macular degeneration. J Korean Ophthalmol Soc 2013;54:1359-64. https://doi.org/10.3341/jkos.2013.54.9.1359
- DiLoreto DA Jr, Bressler NM, Bressler SB, Schachat AP. Use of best and final visual acuity outcomes in ophthalmological research. Arch Ophthalmol 2003;121:1586-90. https://doi.org/10.1001/archopht.121.11.1586
- Chong V. Ranibizumab for the treatment of wet AMD: a summary of real-world studies. Eye (Lond) 2016;30:270-86. https://doi.org/10.1038/eye.2015.217
- Frennesson CI, Nilsson SE. A three-year follow-up of ranibizumab treatment of exudative AMD: impact on the outcome of carrying forward the last acuity observation in drop-outs. Acta Ophthalmol 2014;92:216-20. https://doi.org/10.1111/aos.12091
- Rofagha S, Bhisitkul RB, Boyer DS, et al. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology 2013;120:2292-9. https://doi.org/10.1016/j.ophtha.2013.03.046
- Gillies MC, Campain A, Barthelmes D, et al. Long-term outcomes of treatment of neovascular age-related macular degeneration: data from an observational study. Ophthalmology 2015;122:1837-45. https://doi.org/10.1016/j.ophtha.2015.05.010
- Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Maguire MG, Martin DF, et al. Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials. Ophthalmology 2016;123:1751-61. https://doi.org/10.1016/j.ophtha.2016.03.045
- Peden MC, Suner IJ, Hammer ME, Grizzard WS. Long-term outcomes in eyes receiving fixed-interval dosing of anti-vascular endothelial growth factor agents for wet age-related macular degeneration. Ophthalmology 2015;122:803-8. https://doi.org/10.1016/j.ophtha.2014.11.018
- Holz FG, Tadayoni R, Beatty S, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol 2015;99:220-6. https://doi.org/10.1136/bjophthalmol-2014-305327
- Rasmussen A, Bloch SB, Fuchs J, et al. A 4-year longitudinal study of 555 patients treated with ranibizumab for neovascular age-related macular degeneration. Ophthalmology 2013;120:2630-6. https://doi.org/10.1016/j.ophtha.2013.05.018
- Grunwald JE, Pistilli M, Ying GS, et al. Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology 2015;122:809-16. https://doi.org/10.1016/j.ophtha.2014.11.007
- Xu L, Mrejen S, Jung JJ, et al. Geographic atrophy in patients receiving anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Retina 2015;35:176-86. https://doi.org/10.1097/IAE.0000000000000374
- Sarks J, Tang K, Killingsworth M, et al. Development of atrophy of the retinal pigment epithelium around disciform scars. Br J Ophthalmol 2006;90:442-6. https://doi.org/10.1136/bjo.2005.083022
- Tanaka E, Chaikitmongkol V, Bressler SB, Bressler NM. Visionthreatening lesions developing with longer-term follow-up after treatment of neovascular age-related macular degeneration. Ophthalmology 2015;122:153-61. https://doi.org/10.1016/j.ophtha.2014.07.046
- Munk MR, Ceklic L, Ebneter A, et al. Macular atrophy in patients with long-term anti-VEGF treatment for neovascular age-related macular degeneration. Acta Ophthalmol 2016;94:e757-64. https://doi.org/10.1111/aos.13157
- Bhisitkul RB, Mendes TS, Rofagha S, et al. Macular atrophy progression and 7-year vision outcomes in subjects from the ANCHOR, MARINA, and HORIZON studies: the SEVEN-UP study. Am J Ophthalmol 2015;159:915-24.e2. https://doi.org/10.1016/j.ajo.2015.01.032
Cited by
- Incidence and Clinical Features of Rhegmatogenous Retinal Detachment After 9,484 Intravitreal Injections by a Single Physician vol.5, pp.2, 2020, https://doi.org/10.21561/jor.2020.5.2.79